Functional analysis of synovial sarcoma specific fusion-gene and identification of new therapeutic targets

2017 Fiscal Year Final Research Report

• Project/Area Number: 26462264
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Orthopaedic surgery
• Research Institution: Osaka University
• Principal Investigator: Kenichiro Hamada 大阪大学, 医学系研究科, 助教 (50649043)
• Co-Investigator(Kenkyū-buntansha): 王谷 英達 大阪大学, 医学系研究科, 特任助教(常勤) (60727965) ; 中 紀文 地方独立行政法人大阪府立病院機構大阪国際がんセンター(研究所), その他部局等, 整形外科主任部長 (90601964)
• Project Period (FY): 2014-04-01 – 2018-03-31
• Keywords: 滑膜肉腫 / 新規治療開発 / 融合遺伝子

Outline of Final Research Achievements

Synovial sarcoma is a rare aggressive disease which is characterized by a synovial sarcoma specific fusion-oncogene SS18-SSX. We examined the possibility to control the tumors by silencing SS18-SSX using doxycycline inducible system. Then, we successfully suppressed the tumor growth by silencing the fusion-oncogene SS18-SSX both in vitro and in vivo using this system. In addition, we confirmed that silencing of SS18-SSX resulted in significantly less tumor formations in vivo. These results indicated that silencing of SS18-SSX could be a treatment option for local tumors or metastases. Furthermore, we are now analyzing gene expressions regulated by SS18-SSX using this system to explore a new treatment target for synovial sarcoma.

Free Research Field

骨軟部腫瘍